

Page 1 of 3 -Attorney Docket No.: 21486-032

a plus sign (+) in this box

Modified Form 1449/PTO

B5

ΕP

0 180 188 A2

05/07/86

09/436,184

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number**

MOGINEO	O11111 1-4-4	3/1- 1-0				•		- (p p : 0 = 1 : 0 : 1 : 1 : 1		_,		
								Filing Date	Nove	mber 8, 1	999	
INFORMATION DISCLOSURE First Named Inventor						Wands 1643 Karen A. Canella						
STATEMENT BY APPLICANT Group Art Unit												
(use as many sheets as necessary) Examiner Name Attorney Docket Number												
							Attorney Docket Number	21486-032				
					-	U.S	. PA	TENT DOCUMENTS				
Exam Initials	Cite No.			Issue Date		Na	Name of Patentee(s) or Applicant(s)		Class	Sub Class	s	Filing Date If Appropriate
/KAC/	A1	4,7	4,735,210		04/05/88		Goldenberg			654		
	A2	5,789,426 5,814,500 5,830,478		08/26/97 08/04/98 09/29/98 11/03/98		Thorpe et al. Hanauske-Abel et al. Dietz		424 514 435	152.	.1		
	A3								348	十	·	
	A4								172.	.3		
	A5					Ra	Raso et al.			236.	.1	
	A6			12/	12/22/98		Ullrich et al.		154	44	\dashv	
	A7 5,854,205		12/29/98		ļ o	O'Reilly et al.			2	_		
	A8 5,939,531 08/17/			17/99	7/99 Wels		et al.	530	387.	.3	······································	
	A9	6,	165,464	12/26/00			Hudziak et al.			142.	1	
V	A10		7,160,885 B2		01/09/07		Currie et al.		514	249	_	
		-	· · · · · · · · · · · · · · · · · · ·	. :								
					U.S.			APPLICATION DOCUMENTS				
Exam Initials	Cite No.	U.S. Published Application No.		Published Date			Nan	ne of Patentee(s) or Applicant(s)	Class	Sub Class		Filing Date If Appropriate
/KAC/	A11	2005/0113329 A		1 05/26/05		/05	Wa	inds et al.	514	 		
/KAC/	A12	2005/0123545 A		1 06/09/05		/05	Wa	inds et al.	424	146.1	l ·	
/KAC/	A13	2006/0211058 A1 09/21/		/06 Wands et al.		435	7.23					
		•		•		FOREIG	N P	ATENT DOCUMENTS				
Exam Initials	Cite No.	Foreign Patent Document Office Number			Name	Name of Patentee(s) or Applicant(s)			Date of Publication		Translation Yes No	
/KAC/	B2	WO 98/19691			THE GENERAL HOSPITAL CORPORATION			05/14/	98			
/KAC/	В3	WO 98/56387			UNISEARCH LIMITED			12/17/	98			
/KAC/	B4	WO 99/01020				HUMA	HUMAN GENOME SCIENCES, INC.			99		
	1		· · · · · · · · · · · · · · · · · · ·	_								

OTSUKA PHARMACEUTICALS CO.,

LTD.

Express Mail No.: EV 978772687 US Page 2 of 3
Date of Deposit: October 9, 2007 Attorney Docket No.: 21486-032

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. Baron et al., "Insulin Receptor-Induced Phosphorylation of Cellular and Synthetic Substrates Is Regualted by the Recepetor β-Subunit C-Terminus", Endocrinol., 137(8) 3416-23 (1996)						
/KAC/	C44							
	C45	Boder et al., "Directed Evolution of Antibody Fragments with Monovalent Femtomolar Anitgen-Binding Affinity", PNAS, 97(20):10701-10705 (2000)						
	C46	Boutin et al., Differentiation Res. Biol. Diversity, Abstract only, 48(2):99-105 (1991)						
	C47	Clark, M., "Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man", Academic Titles, General Introduction, page 1 (1993)						
	C48	De la Monte et al., "Aspartyl (Asparaginyl) Beta Hydroxylase (AAH) Expression Marks Invasiveness of Primary Malignant CNS Neoplasms", Abstract only , <i>Lab. Invest.</i> , 79(1):1000 (1999)						
	C49	DeWys et al., "Studies on the Effect of Tumor Type and Route of Administration on the Antitumor Activity of the Amino Acid Mimosine (NSC-69188)", Cancer Chemother. Rep., 57(1 – Part 1):41-49 (1973)						
	C50	Dinchuk, et al., "Aspartyl β-Hydroxylase (Asph) and an Evolutionarily Conserved Isoform of Asph Missing the Catalytic Domain Share Exons with Junctin," <i>J. Biol. Chem.</i> , 275(50):39543-39554 (2000)						
	C51	Dinchuk et al., "Absence of Post-translational Aspartyl β-Hydroxylation of Epidermal Growth Factor Domains in Mice Leads to Developmental Defects and an Increased Incidence of Intestinal Neoplasia", <i>J. Biol. Chem.</i> , 277(15):12970-12977 (2002)						
	C52	Dorland's Pocket Medical Dictionary, 23 rd Edition, W.B. Saunders Co., page 246 (1982)						
	C53	Foote et al., "Breaking the Affinity Ceiling for Antibodies and T Cell Receptors", PNAS, 97(20):10679 10681 (2000)						
	C54	GENBANK Accession No. JS0670 (1999)						
	C55	GENBANK Accession No. NM_005544 (2000)						
	C56	GENBANK Accession No. S83325 (1997)						
	C57	Goding, J. W., "Monoclonal Antibodies: Principles and Practice", pgs. 1-4 (1986)						
	C58	Huse, W., Antibody Engineering, "Combinatorial Antibody Expression Libraries in Filamentous Phage", Chapter 5, pgs. 103-107 (1992)						
	C59	Ince et al., "The Insulin Substrate-1 (HIRS-1) Signal Transduction Pathway Influences Expression or Human Aspartyl (Asparginyl) Beta-Hydroxylase (HAAH) in Human Hepato-Cellular Carcinoma Cells" Hepatol., Abstract #1398, page 1398 (1999)						
	C60	Kerr et al., "Common Immunological Techniques", Immunochem. LabFax, pg. 193 (1994)						
	C61	Kieke et al., "Selection of Functional T Cell Receptor Mutants From a Yeast Surface-Display Library" Proc. Natl. Acad. Sci. USA, 96:5651-5656 (1999)						
	C62	Lebowitz et al., "Human aspaetul (Asparaginyl) Beta-hydroxylase is a serum biomarker of breast, ovarian, and prostate cancer", <i>Proceedings of the American Association for Cancer Research</i> , Abstract #2408, 44:471 (2003)						
	C63	Ogawa et al., "Role of binding proteins to IRS-1 in insulin signalling", Mol. Cell. Biochem., 182:13-22 (1998)						
	C64	Palumbo et al., "Human Aspartyl (Asparaginyl) Beta-Hydrozylase Monoclonal Antibodies: Potential Biomarkers for Pancreatic Carcinoma", <i>Pancreas</i> , 25(1):39-44 (2002)						
	C65	Radosevich et al., "Monoclonal Antibody 44-3A6 as a Probe for a Novel Antigen Found on Human Lung Carcinomas with Glandular Differentiation", Cancer Res., 45:5808-5812 (1985)						
	C66	Schlom, J., "Monoclonal Antibodies: They're More and Less than You Think", <i>Mol. Foundations Oncol.</i> , Ed. S. Broder, pgs. 95-134 (1991).						
V	C67	Sepe et al., "Role of the Aspartyl-Asparaginyl-Beta-Hydroxylase Gene in Neuroblastoma Cell Motility", Lab. Invest., 82(7):881-889 (2002)						

Express Mail No.: EV 978772687 US Date of Deposit: October 9, 2007

Page 3 of 3 Attorney Docket No.: 21486-032

/KA	C68	Sinkule et al., "Monocional Antibody 44-3A6 Doxorubicin Immunoconjugates: Comparative in vitro Anti-Tumor Efficacy of Different Conjugation Methods", <i>Tumor Biol.</i> , 12:198-206 (1991)
	C69	Spencer-Dene et al., Gastroenterol., Abstract only, 130(4):1233-1244 (2006)
	C70	Teillac et al., Annales d'Urologie (France), English Abstract only, 24(1):37-41 (1990)
1	C71	The Sigma Catalog, "Biochemicals and Reagents for Life Science Research", pg. 729 (1997)
	C72	Tomida et al., Anti-Cancer Drug Design, Abstract only, 14(2):169-177 (1999)
	C73	Treves et al., "Molecular Cloning, Expression, Functional Characterization, Chromosomal Localization, and Gene Structure of Junctate, a Novel Integral Calcium Binding Protein of Sarco(endo)plasmic Reticulum Membrane", 275(50):39555-39568 (2000)
	C74	Weg-Remers et al., "Soluble CD44 and CD44v6 Serum Levels in Patients with Colorectal Cancer at Independent of Tumor Stage and Tissue Expression of CD44v6", Am. J. Gastroenterol., 93(5):790-794 (1998)
	C75	White, M. F., "The IRS-signalling system: A network of docking proteins that mediate insulin action", Mol. Cell. Biochem., 182:3-11 (1998)
	C76	Wright et al., J. Pathol., Abstract only, 162(4):279-284 (1990)
\overline{V}	C77	Xian et al., "Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma", Modern Pathol., 19:280-286 (2006)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _______, filed _______, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	01/07/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4136227v.1